EGFR GENE MUTATION
Clinical trials for EGFR GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR GENE MUTATION trials appear
Sign up with your email to follow new studies for EGFR GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug combo before surgery shows promise for EGFR-Positive lung cancer
Disease control OngoingThis study tests a two-step treatment for people with a specific type of lung cancer (EGFR-mutant, stages II to IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, surgery …
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated May 26, 2026 08:18 UTC
-
New combo therapy shows promise for tough lung cancer mutations
Disease control OngoingThis study compares a standard targeted therapy (osimertinib) alone versus the same drug plus chemotherapy for people with advanced non-small cell lung cancer that has both EGFR and TP53 gene mutations. About 294 participants will be randomly assigned to one of the two treatments…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE3 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated May 26, 2026 08:09 UTC
-
New combo therapy targets tough cancers with gene mutations
Disease control OngoingThis early-phase study tests the safety and best dose of the drug neratinib combined with everolimus, palbociclib, or trametinib in people with advanced solid tumors that have not responded to standard treatments. Participants must have certain gene changes (EGFR, HER2, HER3, HER…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Immunotherapy duo plus radiation shows promise in lung cancer trial
Disease control OngoingThis early-phase trial is testing whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this approach ca…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy aims to stall lung cancer progression
Disease control OngoingThis study tests whether adding ramucirumab to the standard drug osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant) live longer without their disease getting worse. About 160 adults with advanced or metastatic non-small cell lung cancer that ha…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: Xiuning Le • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Smartphone app and fitbit join forces to monitor lung cancer treatment side effects
Knowledge-focused OngoingThis study involves 30 lung cancer patients taking oral targeted therapy. They will use a smartphone app, a Fitbit, and a smart pill cap to track symptoms and medication use for up to 24 weeks. The goal is to see if this remote monitoring system is practical and can help improve …
Matched conditions: EGFR GENE MUTATION
Phase: NA • Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated May 18, 2026 12:03 UTC